factual

Combined CTLA-4 and PD-1 blockade gives 55% 10-year survival

Combining the anti-CTLA-4 checkpoint blockade with anti-PD-1 (a different checkpoint discovered by Tasuku Honjo, Arlene Sharp, and Gordon Freeman) produced, in a gold-standard randomized trial of over a thousand patients across 10 countries with 10-year follow-up, 55% of metastatic melanoma patients still alive—transforming an almost uniformly fatal disease into one where more than half are cured.

factualpending

Speaker

James P. Allison

Evidence Quote

“10 years follow up, 55% of the patients were still alive.”

Source

303 | James P. Allison on Fighting Cancer with the Immune System— Sean Carroll's Mindscape
Created: 6/13/2026, 12:24:01 AM

Your notes

Loading notes...